In this issue:
Antioxidants for treatment-related toxicity in childhood leukaemia
Tafasitamab plus lenalidomide in R/R DLBCL
Stage I-II nodular lymphocyte-predominant HL
Impact of GVHD and GVL based on MRD in Ph-positive ALL
Genetic markers in CLL treated with obinutuzumab and venetoclax
CNS prophylaxis with intrathecal chemo in DLBCL
Selinexor in R/R DLBCL
Treatment of frail/elderly patients with Ph-negative ALL
Intermediate-dose cytarabine for AML
Real-world outcomes of ALL treated with inotuzumab
Please login below to download this issue (PDF)